ArticleNPJ science of food2022
Regulation of viable/inactivated/lysed probiotic Lactobacillus plantarum H6 on intestinal microbiota and metabolites in hypercholesterolemic mice.
Article in NPJ science of food, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Postbiotics Formulation and Therapeutic Effect in Inflammation: A Systematic Review.Nutrients · 2025Pooled it
- A novel exopolysaccharide fromGut microbes · 2026Article
- Effects of Hedan Tablets Combined With Simvastatin on Hyperlipidemia: Insights From Microbiomics and Metabolomics.Biomedical chromatography : BMC · 2026Article
- Multiple Probiotic Lactic Acid Bacteria with Marked Cholesterol-Lowering Effects Were Discovered in Equine Colostrum.International journal of molecular sciences · 2026Article
- Heat-Inactivated Lactiplantibacillus plantarum H6 Potentiates Low-Dose Simvastatin Efficacy Against Hypercholesterolemia in Mice Through Gut Microbiota Modulation.Probiotics and antimicrobial proteins · 2026Article
- Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential.Probiotics and antimicrobial proteins · 2026Review
- Combined Effect ofFoods (Basel, Switzerland) · 2026Article
- Genomic Characterization, Safety Assessment, and Probiotic Potential of a Novel Human-DerivedMicroorganisms · 2026Article
- Effects of Tibetan Sheep-Derived Compound Probiotics on Growth Performance, Immune Function, Intestinal Tissue Morphology, and Intestinal Microbiota in Mice.Probiotics and antimicrobial proteins · 2025Article
- Emerging Nonthermal Technologies for the Production of Postbiotics.Comprehensive reviews in food science and food safety · 2025Review
- Microbiota Modulation as an Approach to Prevent the Use of Antimicrobials Associated with Canine Atopic Dermatitis.Biomedicines · 2025Review
- Effect of Probiotics ContainingFoods (Basel, Switzerland) · 2025Review
- Cholesterol-Lowering Mechanism ofNutrients · 2025Article
- [Electroacupuncture at Zusanli improves blood lipid disorders in hyperlipidemic mice by improving gut microbiota structure].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- The Role of Inactivation Methods in Shaping Postbiotic Composition and Modulating Bioactivity: A Review.Foods (Basel, Switzerland) · 2025Review
- Article
- Lauric-α-linolenic lipids modulate gut microbiota, preventing obesity, insulin resistance and inflammation in high-fat diet mice.NPJ science of food · 2024Article
- The Immunomodulatory Effects and Applications of Probiotic Lactiplantibacillus plantarum in Vaccine Development.Probiotics and antimicrobial proteins · 2024Review
- Postbiotics fromFoods (Basel, Switzerland) · 2024Article
- Effects of Probiotic-Fermented Feed on the Growth Profile, Immune Functions, and Intestinal Microbiota of Bamei Piglets.Animals : an open access journal from MDPI · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Evidence suggests that probiotic interventions reduce non-communicable diseases (NCDs) risk. However, its therapeutic effect and mechanism are still unclear. To evaluate the hypocholesterolemic effect of Lactobacillus plantarum H6 (L.p H6), a new commercial patent strain capable of preventing hypercholesterolemia, and its mechanism in depth, three states of the strain were prepared, namely, viable (vH6), heat-inactivated (iH6), and ultrasonically-lysed (uH6) bacteria cells. The results showed that v/i/uH6 cells could lower serum and liver blood lipid levels, alleviate liver damage and improve glucose tolerance test (GTT) and insulin tolerance test (ITT) indexes. v/i/uH6 cells improved the gut microbial composition and significantly reduced the Firmicutes to Bacteroidetes ratio (F/B ratio) in feces. In particular, Muribaculaceae may be a potential biomarker for effective cholesterol reduction. Also, the recovery of these biochemical indices and gut microbiome was found following fecal microbiota transplantation (FMT) using stool from vH6 treated mice. The v/i/uH6 cells increased the intestinal flora metabolism of vitamins-cofactors, as well as amino acids, while decreasing the relative content of primary bile acids. The Pearson correlation analysis showed that norank_f__Muribaculaceae and Lactobacillus had a negative correlation with blood lipid levels. Overall, v/i/uH6 cells were effective in improving hypercholesterolemia in mice, and this effect was attributed partly to the regulation of intestinal microbiota and metabolites related to lipid metabolism. Our findings provided a theoretical basis for the industrial development of probiotics and postbiotics and the treatment of cholesterol diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.